<i>In vitro</i> activity assessment of cefiderocol against Enterobacterales, <i>Pseudomonas aeruginosa,</i> and <i>Acinetobacter</i> spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals.
第一作者:
John H,Kimbrough
第一单位:
JMI Laboratories/Element Iowa City, North Liberty, Iowa, USA.
作者:
主题词
抗菌药(Anti-Bacterial Agents);铜绿假单胞菌(Pseudomonas aeruginosa);微生物敏感性试验(Microbial Sensitivity Tests);不动杆菌属(Acinetobacter);美国(United States);欧洲(Europe);人类(Humans);头孢菌素类(Cephalosporins);β-内酰胺酶类(beta-Lactamases);医院(Hospitals);细菌蛋白质类(Bacterial Proteins);肠杆菌科(Enterobacteriaceae);β内酰胺类(beta-Lactams);卡巴配能类(Carbapenems);抗药性, 多种, 细菌(Drug Resistance, Multiple, Bacterial)
DOI
10.1128/spectrum.01474-24
PMID
39387599
发布时间
2024-11-07
- 浏览0

Microbiology spectrum
2024年12卷11期
e0147424页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文